MALDI mass spectrometry imaging of dopamine and PET D1 and D2 receptor ligands in rodent brain tissues

• Both pharmaceutical and neurobiological research require a molecular understanding of the complex biochemistry occurring in the brain at a molecular level. To date, this has relied on indirect measurement of labelled compounds or by sample homogenization and subsequent analysis. However, recent advancements in the field of mass spectrometry imaging (MSI) now enabled the direct analysis of molecules from tissue sections. Drugs and endogenous compounds can be simultaneously desorbed/ionized and their abundance measured and mapped across a tissue section, in a multiplexed way. The technologies allow near cellular spatial resolution analysis and quantitative data to be collected. Sample preparation is a crucial step for successful target analyte detection. The use of standard solvent based and novel solvent-free MALDI matrix application methods have been reported as effective for label-free detection of D1 and D2 dopamine receptor antagonists. Furthermore, recently published protocols describe how neurotransmitters previously undetectable directly by MSI can be successfully analyzed following on-tissue derivatization. Mass spectrometry imaging is becoming established as a significant tool for neuroscience and pharmaceutical research and development.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

Derivatization

Dopamine

Dry matrix

Imaging

Label-free

MALDI

Mass spectrometry imaging

Neurotransmitter

PET ligand

Raclopride

Publikations- och innehållstyp

ref (ämneskategori)

kap (ämneskategori)